

# Eric D Bateman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4820265/publications.pdf>

Version: 2024-02-01

141  
papers

21,959  
citations

16451  
64  
h-index

11052  
137  
g-index

142  
all docs

142  
docs citations

142  
times ranked

14573  
citing authors

#	ARTICLE	IF	CITATIONS
1	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 2014, 43, 343-373.	6.7	2,898
2	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 59-99.	5.6	1,591
3	Can Guideline-defined Asthma Control Be Achieved?. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 836-844.	5.6	1,489
4	Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 2012, 12, 204.	2.9	1,106
5	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respiratory Medicine, 2015, 3, 355-366.	10.7	937
6	Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respiratory Medicine, 2006, 100, 616-621.	2.9	795
7	A summary of the new GINA strategy: a roadmap to asthma control. European Respiratory Journal, 2015, 46, 622-639.	6.7	636
8	Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 129-136.	5.6	593
9	Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. New England Journal of Medicine, 2012, 367, 1198-1207.	27.0	578
10	Inhaled Combined Budesonide/Formoterol as Needed in Mild Asthma. New England Journal of Medicine, 2018, 378, 1865-1876.	27.0	453
11	COPD in Never Smokers. Chest, 2011, 139, 752-763.	0.8	444
12	Roflumilast "an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2005, 366, 563-571.	13.7	443
13	A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol. Chest, 2002, 122, 47-55.	0.8	428
14	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine, 2016, 4, 781-796.	10.7	398
15	As-Needed Budesonide/Formoterol versus Maintenance Budesonide in Mild Asthma. New England Journal of Medicine, 2018, 378, 1877-1887.	27.0	368
16	Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal, 2013, 42, 1484-1494.	6.7	358
17	Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD) Tj ETQq1 1 0.784314 rgBT /Overl	6.7	294
18	Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine, 2013, 1, 51-60.	10.7	279

#	ARTICLE	IF	CITATIONS
19	GINA 2019: a fundamental change in asthma management. European Respiratory Journal, 2019, 53, 1901046.	6.7	277
20	Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet, The, 2012, 380, 889-898.	13.7	243
21	Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 2010, 125, 600-608.e6.	2.9	219
22	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	6.7	218
23	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	5.6	196
24	Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. Thorax, 2014, 69, 465-473.	5.6	190
25	Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. Journal of Allergy and Clinical Immunology, 2011, 128, 315-322.	2.9	185
26	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
27	The Global Initiative for Asthma (GINA): 25 years later. European Respiratory Journal, 2019, 54, 1900598.	6.7	174
28	Within-Subject Variability and Boosting of T-Cell Interferon- $\gamma$ Responses after Tuberculin Skin Testing. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 49-58.	5.6	169
29	Efficacy and safety of twice-daily acclidinium bromide in COPD patients: the ATTAIN study. European Respiratory Journal, 2012, 40, 830-836.	6.7	168
30	Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. European Respiratory Journal, 2015, 46, 1104-1112.	6.7	159
31	Efficacy and safety of acclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulmonary Medicine, 2014, 14, 178.	2.0	156
32	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respiratory Medicine, the, 2015, 3, 367-376.	10.7	153
33	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respiratory Medicine, the, 2014, 2, 267-276.	10.7	149
34	Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax, 2012, 67, 781-788.	5.6	147
35	The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. Lancet Respiratory Medicine, the, 2015, 3, 719-728.	10.7	142
36	Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation. JAMA - Journal of the American Medical Association, 2014, 312, 155.	7.4	135

#	ARTICLE	IF	CITATIONS
37	Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 441-450.e8.	2.9	133
38	The paradoxes of asthma management: time for a new approach?. <i>European Respiratory Journal</i> , 2017, 50, 1701103.	6.7	130
39	Roflumilast with long-acting $\beta_2$ -agonists for COPD: influence of exacerbation history. <i>European Respiratory Journal</i> , 2011, 38, 553-560.	6.7	117
40	A Systematic Review of the Association between Pulmonary Tuberculosis and the Development of Chronic Airflow Obstruction in Adults. <i>Respiration</i> , 2013, 86, 76-85.	2.6	116
41	Alternative mechanisms for tiotropium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 533-542.	2.6	109
42	A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. <i>European Respiratory Journal</i> , 2012, 39, 1220-1229.	6.7	105
43	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
44	Integrating real-life studies in the global therapeutic research framework. <i>Lancet Respiratory Medicine</i> , 2013, 1, e29-e30.	10.7	102
45	Acclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and) Tj ETQq1 1 0.784314 rgBTz/Over	3.9	97
46	Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events. <i>Annals of Internal Medicine</i> , 2008, 149, 33.	3.9	97
47	Fevipirant, an oral prostaglandin DP <sub>2</sub> receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. <i>European Respiratory Journal</i> , 2017, 50, 1700670.	6.7	93
48	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1457-1464.e4.	2.9	88
49	Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. <i>Respiratory Medicine</i> , 2016, 117, 198-206.	2.9	87
50	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
51	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. <i>Chest</i> , 2013, 144, 1222-1229.	0.8	86
52	Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 563-570.	2.9	84
53	Efficacy and safety of roflumilast in the treatment of asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 679-686.	1.0	82
54	Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 37-44.	2.6	78

#	ARTICLE	IF	CITATIONS
55	Combined Analysis of Asthma Safety Trials of Long-Acting $\beta_2$ -Agonists. New England Journal of Medicine, 2018, 378, 2497-2505.	27.0	76
56	Occupational allergy and asthma among salt water fish processing workers. American Journal of Industrial Medicine, 2008, 51, 899-910.	2.1	74
57	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax, 2014, 69, 312-319.	5.6	73
58	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax, 2012, 67, 35-41.	5.6	72
59	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. European Respiratory Journal, 2014, 43, 773-782.	6.7	72
60	Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma control study. Journal of Allergy and Clinical Immunology, 2007, 120, 1036-1042.	2.9	71
61	Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma. Treatments in Respiratory Medicine, 2003, 2, 275-281.	1.2	69
62	High Prevalence of Tuberculosis in Previously Treated Patients, Cape Town, South Africa. Emerging Infectious Diseases, 2007, 13, 1189-1194.	4.3	69
63	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the $\beta_2$ -agonist vilanterol administered once daily for 52 weeks in patients $\geq 12$ years old with asthma: a randomised trial. Thorax, 2013, 68, 513-520.	5.6	69
64	Airflow Obstruction and Use of Solid Fuels for Cooking or Heating. BOLD (Burden of Obstructive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	5.6	69
65	Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 589-596.e3.	3.8	69
66	Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. Respiratory Medicine, 2012, 106, 642-650.	2.9	67
67	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, S1-S18.	3.8	66
68	Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 923-935.e9.	3.8	64
69	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. European Respiratory Journal, 2014, 44, 1156-1165.	6.7	60
70	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory Research, 2011, 12, 38.	3.6	58
71	Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology, 2015, 136, 914-922.	2.9	58
72	Overdiagnosis of COPD in Subjects With Unobstructed Spirometry. Chest, 2019, 156, 277-288.	0.8	57

#	ARTICLE	IF	CITATIONS
73	ARIAâ€EACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
74	Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1353-1365.	5.6	52
75	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	6.7	50
76	Short-acting $\beta_2$ -agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. European Respiratory Journal, 2022, 59, 2101402.	6.7	50
77	A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respiratory Medicine, 2007, 101, 1677-1686.	2.9	49
78	Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. Journal of Allergy and Clinical Immunology, 2016, 138, 142-149.e8.	2.9	49
79	Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. International Journal of COPD, 2010, 5, 197-208.	2.3	48
80	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Annals of Allergy, Asthma and Immunology, 2012, 109, 353-358.e4.	1.0	47
81	Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma. Chest, 2006, 129, 1176-1187.	0.8	46
82	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
83	Effect of a single day of increased as-needed budesonideâ€formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine, 2021, 9, 149-158.	10.7	46
84	Asthma management in low and middle income countries: case for change. European Respiratory Journal, 2022, 60, 2103179.	6.7	45
85	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respiratory Research, 2011, 12, 160.	3.6	42
86	Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respiratory Research, 2011, 12, 132.	3.6	42
87	Fluticasone Furoateâ€Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 553-561.	3.8	40
88	Efficacy and safety of fluticasone furoate 100Â¼g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. Respiratory Medicine, 2014, 108, 41-49.	2.9	37
89	Helsinki by nature: The Nature Step to Respiratory Health. Clinical and Translational Allergy, 2019, 9, 57.	3.2	36
90	Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 581-587.	2.6	35

#	ARTICLE	IF	CITATIONS
91	Fluticasone furoate (FF)/vilanterol (100/25â€‰mcg or 200/25â€‰mcg) or FF (100â€‰mcg) in persistent asthma. <i>Journal of Asthma</i> , 2015, 52, 1073-1083.	1.7	35
92	A Practical Guide to Implementing SMART in Asthma Management. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S31-S38.	3.8	34
93	Prevalence and Characteristics of Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1143-1150.	3.2	32
94	Safety and tolerability of once-daily tiotropium Respimat Â® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. <i>Respiratory Medicine</i> , 2016, 118, 102-111.	2.9	31
95	Global Initiative for Asthma Strategy 2021. <i>Respirology</i> , 2022, 27, 14-35.	2.3	31
96	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. <i>Archivos De Bronconeumologia</i> , 2022, 58, 35-51.	0.8	31
97	Development of a South African integrated syndromic respiratory disease guideline for primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2008, 17, 156-163.	2.3	30
98	Recent advances in COPD disease management with fixed-dose long-acting combination therapies. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 357-379.	2.5	30
99	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given â€“as neededâ€™ in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12.	1.6	30
100	What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. <i>Respirology</i> , 2020, 25, 804-815.	2.3	29
101	Rate of Response of Individual Asthma Control Measures Varies and May Overestimate Asthma Control: An Analysis of the Goal Study. <i>Journal of Asthma</i> , 2007, 44, 667-673.	1.7	28
102	Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 155-161.	2.3	26
103	Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1171-1180.	5.6	26
104	A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 157-164.	2.2	25
105	&lt;p&gt;Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active Tuberculosis&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1039-1047.	2.3	25
106	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , 2014, 15, 69-82.	2.8	23
107	Efficacy and safety of fluticasone furoate 100Â½g and 200Â½g once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 113.	2.0	22
108	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3069-3077.e6.	3.8	22



#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. <i>Respiratory Research</i> , 2014, 15, 88.	3.6	19
110	Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. <i>European Respiratory Journal</i> , 2016, 47, 651-654.	6.7	19
111	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. <i>Journal of Negative Results in BioMedicine</i> , 2014, 13, 9.	1.4	18
112	Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting &beta;2-agonists in patients with atopic asthma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1093-1106.	4.3	18
113	Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 489-495.	5.6	17
114	Positioning As-needed Budesonide&ldquo;Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2007-2017.	3.2	17
115	Severity of Airflow Obstruction in Chronic Obstructive Pulmonary Disease (COPD): Proposal for a New Classification. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 469-475.	1.6	16
116	Silicosis among gemstone workers in South Africa: Tiger's-eye pneumoconiosis. <i>American Journal of Industrial Medicine</i> , 1991, 19, 205-213.	2.1	15
117	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. <i>Respiratory Medicine</i> , 2022, 191, 105991.	2.9	13
118	As-Needed Budesonide&ldquo;Formoterol in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 379, 897-898.	27.0	11
119	Treatment adherence in asthmatic patients: The last frontier?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1269-1270.	2.9	10
120	Global Initiative for Asthma 2016&ldquo;derived asthma control with fluticasone propionate and salmeterol. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 57-63.e2.	1.0	10
121	Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty: a BOLD analysis&ldquo;authors&ldquo;reply. <i>Thorax</i> , 2014, 69, 869.2-870.	5.6	9
122	Systems for the management of respiratory disease in primary care &ldquo; an international series: South Africa. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2009, 18, 69-75.	2.3	8
123	&lt;p&gt;Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD&lt;p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 615-629.	2.3	8
124	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. <i>Drug Safety</i> , 2021, 44, 467-478.	3.2	8
125	Chronic airflow obstruction and ambient particulate air pollution. <i>Thorax</i> , 2021, 76, 1236-1241.	5.6	7
126	QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla )</i> , 2014, 2, 48-60.	0.7	7



#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of high-dose ciclesonide for the treatment of severe asthma. Expert Review of Respiratory Medicine, 2013, 7, 339-348.	2.5	6
128	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC Pulmonary Medicine, 2017, 17, 65.	2.0	6
129	Lung function defects in treated pulmonary tuberculosis patients. European Respiratory Journal, 2016, 47, 352-353.	6.7	5
130	Lung Diseases in South Africa: An Overview. Novartis Foundation Symposium, 0, , 4-16.	1.1	5
131	Asthma attacks: how can we reduce the risks?. Npj Primary Care Respiratory Medicine, 2015, 25, 14105.	2.6	4
132	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. Respiratory Medicine, 2016, 120, 91-100.	2.9	4
133	Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clinical Respiratory Journal, 2012, 6, 248-257.	1.6	3
134	Salmeterol/Fluticasone Propionate Combination. Drugs, 1999, 57, 941-943.	10.9	1
135	Inhaled Triamcinolone Acetonide HFA 450??g Twice Daily Compared with Beclomethasone Dipropionate CFC 500??g Twice Daily in Adults with Moderate Persistent Asthma. Clinical Drug Investigation, 2000, 20, 9-17.	2.2	1
136	Integrated clinical management tools for respiratory diseases: lessons from PAL in sub-Saharan Africa. International Journal of Tuberculosis and Lung Disease, 2016, 20, 429-429.	1.2	1
137	Reply to: Cause or consequence?. European Respiratory Journal, 2022, 59, 2200103.	6.7	1
138	Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting $\beta_2$ -Agonists". Applied Health Economics and Health Policy, 2016, 14, 117-118.	2.1	0
139	Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma". Respiratory Medicine, 2022, 191, 106088.	2.9	0
140	Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020). Respiratory Medicine, 2022, 191, 106106.	2.9	0
141	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function". Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4179-4180.	3.8	0